← Eichor
Study identifier: NCT06092736 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS)

Condition: Microvascular Angina  ·  Sponsor: Qilu Hospital of Shandong University

PhasePhase 4
Planned participants100
Who can joinAll sexes, 30 Years to 75 Years
Healthy volunteersNo

About this study

Coronary microvascular disease (MVD) refers to exertional angina or myocardial ischemia caused by abnormal structure and/or function of precoronary arterioles and arterioles under the action of various pathogenic factors. The symptoms of patients with coronary microvascular disease are mainly exertion-related chest pain episodes. The basic and clinical researches of the traditional Chinese medicine compound Danshen dropping pills have found that it can improve vascular endothelial function and relieve angina pectoris, and it is widely used in clinical practice. This is a randomized, double-blind, placebo-controlled, multicenter clinical study of Compound Danshen Dropping Pills and blank control in patients with microvascular angina pectoris. The experimental drug and control drug of this clinical trial were selected according to the ratio of 1:1 patients were enrolled in the pre-experiment. After the selected patients signed the informed consent, they were divided into a compound Danshen dripping pill treatment group and a placebo group according to a random, double-blind, placebo-controlled method. Dosage of Compound Danshen Dropping Pills or placebo: 20 capsules each time, 3 times a day, for a total of 6 months. Follow-up was performed every 2 months for a total of 6 months. Primary study endpoints is the difference of the left anterior descending coronary flow reserve (CFR) measured by ultrasound between the two groups compared with the baseline. Secondary study endp…

This description comes directly from the study's public registry record.

Talk to the study team

Yun Zhang, PhD  ·  +86-18560086626  ·  zhangyun@sdu.edu.cn

Xiaoling Liu, PhD  ·  +86-18560086718  ·  xiaolingliusdu@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Qilu Hospital of Shandong UniversityJinan, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06092736